

AGENDA

***Uniform Formulary Beneficiary Advisory Panel
11 June 2015 @ 0900 AM***

***Naval Heritage Center Theater
701 Pennsylvania Ave., N.W., Washington, DC 20004***

- **Administrative Meeting (BAP members only @ 8:45 AM-9:00 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

Members of the DHA Pharmacy Operations Division Formulary Management Branch will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.

The Committee made recommendations for the following drug classes during the May 2015 meeting:

- ***Designated Newly Approved Drugs***
 - ***Newer Sedative Hypnotic Drugs—Suvorexant (Belsomra)***
 - ***Multiple Sclerosis Drugs—Peginterferon beta-1a (Plegridy)***
 - ***Antiemetics/Antivertigo Agents—Doxylamine succinate and pyridoxine hydrochloride (Diclegis)***
- ***Drug Class Reviews:***
 - ***Hepatitis C Virus Drugs: Direct Acting Antivirals***
 - ***Oral Anticoagulants***
- ***Utilization Management Issues***
 - ***Prior Authorization Criteria***
 - ***Testosterone Replacement Therapy—Testosterone Nasal Gel (Natesto)***
 - ***Cystic Fibrosis Drugs—Ivacaftor (Kalydeco)***
 - ***Renin Angiotensin Antihypertensives—Perindopril/amlodipine (Prestalia)***
 - ***Insulins—Inhaled Insulin (Afrezza)***

- *Self-Monitoring Blood Glucose System Test Strips—ACCU-CHEK Aviva Plus Test Strips*

➤ **Panel Discussions**

The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.